Moreover, while BCL6-expressing lymphomas provide a compelling model to explore the therapeutic potential of the BCL6-targeting KAT-TCIPs described here, the widespread expression of p300/CBP across various cancers suggests the broader applicability of CIPs that redirect p300/CBP to pro-apoptotic TFs. Here, BCL6 is linked to lymphoma.